Lorbrexen 100mg (Lorlatinib)

Lorbrexen is a drug indicated for use in the treatment of cancer. Lorbrexen is researched and developed by the leading pharmaceutical company Everest - Bangladesh. Below is detailed information about the drug.

Ingredients of Lorbrexen

• Lorlatinib.....................100mg

Dosage forms

• Tablets.

Uses - Indications of Lorbrexen

• ALK belongs to a family of enzymes called receptor tyrosine kinases, which are involved in the growth of cells and the growth of new blood vessels that supply them.
• In patients with 'ALK positive' NSCLC, an abnormal form of ALK is produced which causes cancer cells to divide and grow in an uncontrolled manner.
• The active ingredient in Lorvrexen, lorlatinib, is a tyrosine kinase inhibitor. It works by blocking the activity of ALK, thereby reducing the growth and spread of cancer cells.

Contraindications of Lorbrexen

• Heart problems, such as "AV block" (unless you have a pacemaker);
• Lung disease, difficulty breathing;
• Liver failure;
• Depression;
• Epileptic;
• High cholesterol or triglycerides

Dosage – How to use Lorbrexen

• How to use: The drug is taken orally.
• Dosage:
  • The recommended dose of lorlatinib is 100 mg PO daily, which can be taken before and after meals until disease progression or unacceptable toxicity.

Notes and precautions when using Lorbrexen

• Significant risk of hepatotoxicity with concurrent use of strong CYP3A inducers: Discontinue the strong CYP3A inducer within 3 plasma half-lives of the strong CYP3A inducer before initiating Lorbrexen.
• Central Nervous System (CNS) Effects: CNS effects include seizures, psychotic effects, and changes in cognitive function, mood, speech, mental status, and sleep .
• Hyperlipidemia: Initiate or increase dose of lipid-lowering medication.
• Atrioventricular block:
• Interstitial Lung Disease/Pneumonia:
• Hypertension: Monitor blood pressure after 2 weeks and then at least monthly during treatment.
• Hyperglycemia: Assess fasting blood glucose before starting Lorbrexen and regularly during treatment. If not adequately controlled with optimal medical management.
• Embryotoxicity: May cause harm to the fetus. Advise women of fertility about the potential risk to the fetus. Advise men and women of reproductive potential to use effective non-hormonal methods of contraception.

Use medicine for pregnant and lactating women

• Lorlatinib may harm an unborn baby or cause birth defects.
• If you are female, please do not use Lorlatinib if you are pregnant. Before starting this treatment, you may need to have a negative pregnancy test. Use effective birth control methods to prevent pregnancy while you are using this medication, and for at least 6 months after your last dose.

For use by drivers and machine operators

• The drug can affect cognition, use caution when driving and operating machinery.

Side effects of Lorbrexen

• The most common adverse reactions (incidence ≥20%) and Grade 3–4 laboratory abnormalities were edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, difficulty breathing, joint pain, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia and cough.

Drug interactions

• Strong CYP3A inducers: Contraindicated.
• Moderate CYP3A inducers: Avoid concomitant use. If coadministration cannot be avoided, increase the Lorbrexen dose.
• Strong CYP3A inhibitors: Avoid concurrent use; Reduce Lorbrexen dose if concurrent use cannot be avoided.
• Fluconazole: Avoid concurrent use; Reduce Lorbrexen dose if concurrent use cannot be avoided.
• Certain CYP3A Substrates: Avoid concomitant use with CYP3A substrates where minimal concentration changes could result in serious treatment failure.
• Certain P-gp substrates: Avoid concurrent use with P-gp substrates where minimal concentration changes could result in serious treatment failure.

Forgot dose and treatment

• Take Lorlatinib at the same time each day. If a dose is missed, the missed dose is discarded unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.

Overdose and treatment

• If you vomit immediately after taking Lorlatinib, do not take another dose. Wait until the next scheduled dose time to take the medicine again.

Packing

• Box of 1 bottle x 30 tablets

Preserve

• Store the medicine in a dry place, away from strong light.

Expiry

• 36 months from date of manufacture.

Manufactured by Lorbrexen

• Everest Pharmaceuticals Ltd.